Is the response to growth hormone in short children born small for gestational age dependent on genetic or maternal factors?
Related Experiment Video
Updated: Jun 20, 2026

Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings
Published on: October 25, 2015
Otto Mehls1, A Lindberg, M Bettendorf
1Division of Paediatric Nephrology, University Hospital for Children and Adolescents, Heidelberg, Germany. Otto.Mehls@med.uni-heidelberg.de
Insights
Genetic and maternal factors do not explain growth response to growth hormone (GH) therapy in children born small for gestational age (SGA). Further research is needed to understand variations in treatment outcomes.
Area of Science:
- Pediatric Endocrinology
- Genetics
- Maternal Health
Background:
- Children born small for gestational age (SGA) often exhibit growth deficits.
- Growth hormone (GH) therapy is used to improve growth in SGA children.
- Variability in GH therapy response necessitates understanding underlying factors.
Purpose of the Study:
- To investigate if genetic or maternal/environmental risk factors explain growth response variability in SGA children treated with GH.
- To analyze the influence of specific conditions like Silver-Russell syndrome, congenital heart defects, maternal infections, and smoking on GH therapy outcomes.
Main Methods:
- Secondary analysis of a phase III trial involving 135 short prepubertal German children with SGA.
- Data included patient demographics, height standard deviation scores (SDS), and GH dosage.
- Statistical analysis, including multivariate analysis, was used to identify influencing factors.
Main Results:
- GH therapy increased growth velocity by 4.5 cm/year and height SDS by 1.0 SDS.
- No significant differences in growth response were observed between subgroups based on genetic or maternal risk factors.
- Multivariate analysis did not identify Silver-Russell syndrome, congenital heart defects, maternal infections, or smoking as independent predictors of growth velocity.
Conclusions:
- Retrospectively analyzed genetic and maternal/environmental risk factors for SGA do not appear to explain the variance in GH therapy response.
- Preliminary findings suggest these factors are not primary drivers of differential growth outcomes.
- Larger prospective studies are required to confirm these results and elucidate factors influencing GH response in SGA children.
Background/Aims:
We investigated whether genetic or maternal/environmental risk factors for being born small for gestational age (SGA), e.g. Silver-Russell syndrome, congenital heart defects, infections of mothers or smoking during pregnancy, explain the variation in the first-year growth response to GH therapy.
Methods:
Secondary analysis was made of growth response in 135 short prepubertal German children (66% males) enrolled in a SGA phase III trial. Initial mean patient age was 6.8 +/- 2.6 years; mean patient height SDS -3.8 +/- 1.2, and GH treatment dose was 0.066 mg/kg body weight per day.
Results:
Growth velocity increased by 4.5 +/- 2.0 cm/year and height SDS by 1.0 +/- 0.5 SDS. Although patient number was limited and variation was high, both growth response (cm/year) and change in height SDS did not appear to differ between subgroups which also did not differ in terms of Studentized residuals set up in the KIGS growth prediction model for SGA. Likewise, in a step-forward multivariate analysis, the variables Silver-Russell syndrome, congenital heart defects, infections of mothers and smoking were not identified as independent factors influencing growth velocity.
Conclusion:
The retrospectively analyzed genetic and maternal/environmental risk factors for SGA do not appear to explain the observed patient variance in response to GH. Larger prospective studies are needed, however, to substantiate these preliminary findings.
Related Concept Videos
Nature and Nurture
Polygenic Traits
Gene-Environment Interactions
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Factors Affecting Drug Response: Overview
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...